ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.Journal of neurology · 2026Article
- Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- OCT in Oncology and Precision Medicine: From Nanoparticles to Advanced Technologies and AI.Bioengineering (Basel, Switzerland) · 2025Review
- Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles.Therapeutic advances in neurological disorders · 2025Article
- Deep Learning and The Retina: A New Frontier in Multiple Sclerosis Diagnosis.Current health sciences journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptical coherence tomography (OCT) is a biomarker of neuroaxonal loss in multiple sclerosis (MS).
objectiveThe objective was to assess the relative role of OCT, next to magnetic resonance imaging (MRI) and serum markers of disability in MS.
methodsA total of 100 patients and 52 controls underwent OCT to determine peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layers (GCIPL). Serum neurofilament light chain (sNfL), total lesion volume (TLV), and brain parenchymal fraction (BPF) were also assessed. The associations of OCT with disability were examined in linear regression models with correction for age, vision, and education.
resultsIn patients, pRNFL was associated with the Symbol Digit Modalities Test (SDMT;
conclusionThe associations of OCT measures with cognitive and physical disability were independent of serum and brain MRI markers of neuroaxonal loss. OCT can be an important tool for stratification in MS, while longitudinal studies using combinations of biomarkers are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.